Cargando…

Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?

INTRODUCTION: Patients with drug addiction have high risk for hepatitis C virus (HCV). Effective treatment response is essential to optimize treatment for drug abusers infected by hepatitis C virus. AIM: The aim of this present study was to show that hepatitis C treatment in patients with drug addic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hojati, Seyed Amineh, Maserat, Elham, Ghorbani, Mohammad, Safarpour, Alireza, Fattehi, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical Sciences of Bosnia and Herzegovina 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282910/
https://www.ncbi.nlm.nih.gov/pubmed/30524163
http://dx.doi.org/10.5455/medarh.2018.72.325-329
_version_ 1783379088226910208
author Hojati, Seyed Amineh
Maserat, Elham
Ghorbani, Mohammad
Safarpour, Alireza
Fattehi, Mohammad Reza
author_facet Hojati, Seyed Amineh
Maserat, Elham
Ghorbani, Mohammad
Safarpour, Alireza
Fattehi, Mohammad Reza
author_sort Hojati, Seyed Amineh
collection PubMed
description INTRODUCTION: Patients with drug addiction have high risk for hepatitis C virus (HCV). Effective treatment response is essential to optimize treatment for drug abusers infected by hepatitis C virus. AIM: The aim of this present study was to show that hepatitis C treatment in patients with drug addiction is effective like patients without drug addiction. MATERIAL AND METHODS: Total amount of 57 patients with hepatitis C (25 drug abuser and 32 non–drug abuser) that referred to Shahid Motahari clinic of Shiraz were selected. All patients infected with HCV treated by combination regimens of ribavirin, sofosbuvir and interferon. Patients received sofosbuvir (400mg once a day) in combination with peg-IFN-alpha (92a180m/w›92b1/5m/kg/w) and RBV (under 75 kg 1000mg, over 75 kg 12000kg) for 12 weeks. The Kolmogorov–Smirnov test was used for testing normality. Associations between variables were analyzed using a Chi-square, Fisher exact, T student and Mann–Whitney U test. RESULTS: Out of 25 HCV patients (43.9%) were drug addicts and 32 patients (56.1%) were non-drug addicts. Insomnia (61.4%), fatigue (63.1%) and debility (49.1%) were more common adverse effects of therapy in drug abusers and non-drug abusers. Alanine transaminase (ALT) and HCV RNA was normal in the end of therapy (EOT). White blood cell (WBC) count decreased in during two-week after starting of the treatment and then increased to normal levels at the end of treatment. Reduction of WBC count was considerable in during two-week. Hematologic result was not considerable. Reduction of hemoglobin was <10 g/dL in 9.37% of non-injecting drug addicts and <8.5 g/dL in 6.25% of injecting drug addicts. The results of this study did not demonstrated a significant relationship about sustained virologic response (SVR) between the drug abusers and non-drug abusers (P = 0.99). CONCLUSIONS: In conclusion, patients with drug addiction can receive hepatitis C treatment on the history of their past or current drug use status. Combination therapy with sofosbuvir plus peginterferon and ribavirin can lead to high treatment response in HCV patients were drug abuser. In addition, this treatment combination was with low discontinuation rates and low adverse effects. Effective intervention in HCV patients with drug addiction to reduce injection- related risk.
format Online
Article
Text
id pubmed-6282910
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Academy of Medical Sciences of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-62829102018-12-06 Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective? Hojati, Seyed Amineh Maserat, Elham Ghorbani, Mohammad Safarpour, Alireza Fattehi, Mohammad Reza Med Arch Original Paper INTRODUCTION: Patients with drug addiction have high risk for hepatitis C virus (HCV). Effective treatment response is essential to optimize treatment for drug abusers infected by hepatitis C virus. AIM: The aim of this present study was to show that hepatitis C treatment in patients with drug addiction is effective like patients without drug addiction. MATERIAL AND METHODS: Total amount of 57 patients with hepatitis C (25 drug abuser and 32 non–drug abuser) that referred to Shahid Motahari clinic of Shiraz were selected. All patients infected with HCV treated by combination regimens of ribavirin, sofosbuvir and interferon. Patients received sofosbuvir (400mg once a day) in combination with peg-IFN-alpha (92a180m/w›92b1/5m/kg/w) and RBV (under 75 kg 1000mg, over 75 kg 12000kg) for 12 weeks. The Kolmogorov–Smirnov test was used for testing normality. Associations between variables were analyzed using a Chi-square, Fisher exact, T student and Mann–Whitney U test. RESULTS: Out of 25 HCV patients (43.9%) were drug addicts and 32 patients (56.1%) were non-drug addicts. Insomnia (61.4%), fatigue (63.1%) and debility (49.1%) were more common adverse effects of therapy in drug abusers and non-drug abusers. Alanine transaminase (ALT) and HCV RNA was normal in the end of therapy (EOT). White blood cell (WBC) count decreased in during two-week after starting of the treatment and then increased to normal levels at the end of treatment. Reduction of WBC count was considerable in during two-week. Hematologic result was not considerable. Reduction of hemoglobin was <10 g/dL in 9.37% of non-injecting drug addicts and <8.5 g/dL in 6.25% of injecting drug addicts. The results of this study did not demonstrated a significant relationship about sustained virologic response (SVR) between the drug abusers and non-drug abusers (P = 0.99). CONCLUSIONS: In conclusion, patients with drug addiction can receive hepatitis C treatment on the history of their past or current drug use status. Combination therapy with sofosbuvir plus peginterferon and ribavirin can lead to high treatment response in HCV patients were drug abuser. In addition, this treatment combination was with low discontinuation rates and low adverse effects. Effective intervention in HCV patients with drug addiction to reduce injection- related risk. Academy of Medical Sciences of Bosnia and Herzegovina 2018-11 /pmc/articles/PMC6282910/ /pubmed/30524163 http://dx.doi.org/10.5455/medarh.2018.72.325-329 Text en © 2018 Seyed Amineh Hojati, Elham Maserat, Mohammad Ghorbani, Alireza Safarpour, Mohammad Reza Fattehi http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Hojati, Seyed Amineh
Maserat, Elham
Ghorbani, Mohammad
Safarpour, Alireza
Fattehi, Mohammad Reza
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title_full Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title_fullStr Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title_full_unstemmed Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title_short Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
title_sort hepatitis c treatment in patients with drug addiction is effective or not effective?
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282910/
https://www.ncbi.nlm.nih.gov/pubmed/30524163
http://dx.doi.org/10.5455/medarh.2018.72.325-329
work_keys_str_mv AT hojatiseyedamineh hepatitisctreatmentinpatientswithdrugaddictioniseffectiveornoteffective
AT maseratelham hepatitisctreatmentinpatientswithdrugaddictioniseffectiveornoteffective
AT ghorbanimohammad hepatitisctreatmentinpatientswithdrugaddictioniseffectiveornoteffective
AT safarpouralireza hepatitisctreatmentinpatientswithdrugaddictioniseffectiveornoteffective
AT fattehimohammadreza hepatitisctreatmentinpatientswithdrugaddictioniseffectiveornoteffective